• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Lupin gets USFDA approval for Sevelamer Carbonate Tablets

expresspharmaJanuary 26, 2021

Tag: lupin , FDA , Sevelamer Carbonate Tablets

Lupin has received approval for its Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration (US FDA), to market a generic equivalent of Renvela Tablets, 800 mg, of Genzyme Corporation.

Sevelamer Carbonate Tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children six years of age and older with chronic kidney disease on dialysis.

Sevelamer Carbonate Tablets (RLD: Renvela) had estimated annual sales of $348 million in the US (IQVIA MAT September 2020).

Previous:Strides get USFDA nod for Ursodiol capsules

Next:Australia approves Pfizer-BioNTech’s Covid-19 vaccine

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Lupin gets USFDA approval for Sevelamer Carbonate Tablets | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

9,9-Bis(4-aminophenyl) Fluorene (FDA)

9,9-Bis(4-aminophenyl) Fluorene (FDA)
Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers

Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers
Dobutamine HCL (FDA)

Dobutamine HCL (FDA)
Cyclosporin A (FDA)

Cyclosporin A (FDA)
Ramantadine( FDA)

Ramantadine( FDA)
Praziquantel (FDA)

Praziquantel (FDA)
Mesnaum (FDA)

Mesnaum (FDA)
GMP/FDA/ISO grade cleanroom system for pharmaceutical cleanroom project

GMP/FDA/ISO grade cleanroom system for pharmaceutical cleanroom project
Adriacin HCL (FDA)

Adriacin HCL (FDA)
Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals

Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service